🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. SR-T100 ® Gel

    Biotech Pharmaceutical Co.,

    Actinic Keratosis

    phase 2 small molecule completed

    1 trial

  2. SSGJ-705

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Locally Advanced, Recurrent or Metastatic Malignancies

    phase 2 small molecule active

    2 trials

  3. SSGJ-706

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    First-line Advanced NSCLC Patients

    phase 2 small molecule active

    1 trial

  4. SSGJ-706+XELOX

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gastric/Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  5. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    NSCLC

    phase 2 small molecule active

    1 trial

  6. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    First-line Advanced NSCLC Patients

    phase 2 small molecule active

    1 trial

  7. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

    phase 2 small molecule active

    1 trial

  8. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  9. SSS06

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chemotherapy-induced Anemia

    phase 2 small molecule active

    1 trial

  10. SSS17

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Anemia in Pre-Dialysis Patients

    phase 2 small molecule completed

    1 trial

  11. SSS17 Capsule (6 Dose Levels)

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Postoperative Anemia

    phase 2 small molecule active

    1 trial

  12. STRO-002

    SUTRO BIOPHARMA, INC.

    Neoplasm Malignant

    phase 2 mab completed

    1 trial

  13. SY-1425, AZACITIDINE

    Lacuna Pharma Pty Ltd

    Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)

    phase 2 small molecule active

    1 trial

  14. Sapropterin

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria

    phase 2 small molecule terminated

    1 trial

  15. Sapropterin

    BioMarin Pharmaceutical Australia Pty Ltd

    GTP Cyclohydrolase Deficiency

    phase 2 small molecule completed

    1 trial

  16. Sapropterin Dihydrochloride

    BioMarin Pharmaceutical Australia Pty Ltd

    Intermittent Claudication

    phase 2 small molecule completed

    1 trial

  17. Sapropterin Dihydrochloride

    BioMarin Pharmaceutical Australia Pty Ltd

    Endothelial Dysfunction

    phase 2 small molecule completed

    1 trial

  18. Sapropterin Dihydrochloride

    BioMarin Pharmaceutical Australia Pty Ltd

    Sickle Cell Disease

    phase 2 small molecule completed

    1 trial

  19. Saruparib, ZYTIGA 500 mg film-coated tablets, Erleada 60 mg film-coated tablets, Saruparib, Xtandi - 40 mg soft capsules, Prednisone Mylan Pharma 5 mg compresse, NUBEQA 300 mg film-coated tablets, Saruparib

    AstraZeneca AB

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  20. Sativex

    Jazz Pharmaceuticals Ireland Limited

    Cancer

    phase 2 small molecule completed

    2 trials

  21. Scemblix 20 mg film-coated tablets, Tasigna 200 mg hard capsules, Scemblix 40 mg film-coated tablets, Tasigna 150 mg hard capsules

    Novartis Pharmaceuticals

    Chronic myeloid leukemia

    phase 2 small molecule active

    1 trial

  22. Scemblix 40 mg film-coated tablets

    Novartis Pharmaceuticals

    CML-CP or CML-AP patients with T315I mutation

    phase 2 small molecule active

    1 trial

  23. Scemblix 40 mg film-coated tablets, Scemblix 40 mg film-coated tablets, Scemblix 20 mg film-coated tablets, Scemblix 40 mg film-coated tablets, NILOTINIB, NILOTINIB, Scemblix 20 mg film-coated tablets, IMATINIB, IMATINIB

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response

    phase 2 small molecule active

    1 trial

  24. Seasonal flu vaccine

    Novartis Pharmaceuticals

    Seasonal Influenza

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources